Dystrophin is a cytoskeletal structural protein normally expressed in skeletal, cardiac and smooth muscles [1]. 
Introduction
Dystrophin is a cytoskeletal structural protein normally expressed in skeletal, cardiac and smooth muscles [1] . [7, 8] . In vascular smooth muscle, both RYR1 and RYR2 are required for Ca 2ϩ release from the SR, although the three RYR sub-types are expressed [9, 10] . The decrease of RYR2 expression in the duodenal muscles of mdx mice was reported [11] , but it has been under debate in the case of cardiac myocytes [12, 13] . Finally, the contraction of portal vein in mdx mice is decreased [14] . In mdx mice and in patients with DMD, the absence of dystrophin is due to a point mutation generating a premature stop codon [15] . Aminoglycoside antibiotics, such as gentamycin, have been described to suppress the nonsense mutation in vivo [16] . This family of antibiotics can restore dystrophin function in mdx skeletal muscle [17] and the mechanotransduction and vasodilation in vascular muscle [18] . These results suggest that aminoglycoside treatment is a putative therapeutic approach for DMD [19] .
In 
Materials and methods

Cell preparation
The 
Gentamycin treatment
The mdx mice were intraperitoneally injected daily with gentamycin (MP Biomedicals Illkirch, France; ref 194530; lot R16139) ]i with an indo-1 set-up, as described elsewhere [11] . No difference was measured in both probe loading and resting [Ca 2ϩ ]i level between myocytes from control and mdx mice (not shown).
RT-PCR
Caffeine was applied by pressure ejection from a glass pipette for the period indicated in the figures. All experiments were carried out at 26 Ϯ 1ЊC.
Solutions
The physiological solution contained (in mM) NaCl 130, KCl 5.6, MgCl2 1, CaCl2 2, glucose 11 and HEPES 10, pH 7.4 , with NaOH. Caffeine was applied to the recorded cell by pressure ejection for the period indicated in the records.
Chemicals and drugs
Collagenase was obtained from Worthington (Freehold, NJ, USA 
Fig. 1 Expression of RYRs in portal vein muscle from control and mdx mice. (A) RT-PCR analysis of RYR1, RYR2, RYR3 and GAPDH mRNAs in freshly dissociated portal vein myocytes for 35 cycles. (B) RT-PCR analysis of RYR2 and GAPDH mRNAs for different cycle protocols. (C) Relative mRNA expression levels of the three RYR sub-types were compared with GAPDH expression in control (open bars) and mdx portal vein myocytes (filled bars). Molecular sizes standards are indicated in bp. Data are means Ϯ S.E., with the number of experiments indicated in parentheses. ଙ, values significantly different from those obtained in control mice (P Ͻ 0.05).
Fig. 2 Western blotting of RYR sub-types expressed in portal vein muscles. RYR sub-types were revealed in proteins extracted from control and mdx mice. InsP3R3 expression was used as control loading (upper panel). Results from three mdx (filled bars) and control (open bars) preparations were normalized to the loading control (lower panel). Data are means Ϯ S.E. with the number of experiments in parentheses. ଙ, values significantly different from those obtained in control mice (P Ͻ 0.05).
Spontaneous Ca 2ϩ sparks in mouse portal vein myocytes
RYR2 in association with
Effect of gentamycin on RYR expression
Gentamycin is an aminoglycoside compound. A property of this molecule family is its ability to shunt stop codon. Here it has been
Fig. 6 Effect of gentamycin on expression of RYRs in portal vein muscle. (A) Relative mRNA expression levels of the three RYR sub-types were revealed by RT-PCR (35 cycles) and compared with GAPDH expression in control (open bars), mdx (filled bars) and gentamycin-treated mdx mice (hatched bars). (B) RYR sub-types were revealed in proteins
